Health Care Reform

Regulators are considering requiring hospitals to use ID numbers to help determine whether big facility fees reflect the care provided.

Grail is focusing on early detection and cutting life insurance market sales teams.

After top drugmakers unsuccessfully tried to squash the program, HHS has finally reached agreements with Merck, Novartis and others to lower prices for the first 10 drugs included in the Medicare Drug Price Negotiation Program.

The purchase is subject to bankruptcy court approval, and the transaction will close pending completion of all closing conditions, including regulatory approval.

A company executive suggested that some competitors may have underpriced their coverage.

Insurers argue that prior authorization is a critical tool for managing excessive or wasteful use of health care services and keeping costs (and ultimately, premiums) in check.